In addition, a few randomized clinical trials performed in patients with periodontitis and osteoarthritis, two chronic inflammatory diseases with progressive tissue degeneration, demonstrated improved tissue repair upon the administration of recombinant human FGF-2 [45, 46]. This evidence concerns the gene FGF2 and osteoarthritis.